From 9 till 12 September 2023: HIGHLIGHTS ON LUNG CANCER
Your direct line with Singapore
The World Conference on Lung Cancer 2023 brings together leading experts in the field of lung cancer from around the world. And, this year they gather together in Singapore. The MediMix team is also onsite, and will – together with your Belgian colleagues – keep you posted about the hottest topics as they happen. And, we dive into posters and hot topics with the experts as they are being presented.
Stay tuned, and get ready for an exciting and informative journey!
With the educational support of
Daily highlights
Dr Eleni Xenophontos, a medical oncologist and clinical research physician at the European Organisation for Research and Treatment of Cancer (EORTC) in Brussels, kindly summarised the recent updates on immunotherapy presented at WCLC.
In her presentation, she discussed the
Prof Annemiek Snoeckx from the University Hospital in Antwerp presented the latest updates on screening at WCLC. One of the main topics that received a lot of attention was recruiting participants in screening trials. Unlike European studies, the meeting mainly
Prof Kevin Lamote from the University of Antwerp researches using exhaled breath’s volatile organic compounds as biomarkers for detecting mesothelioma and lung cancer.
Malignant pleural mesothelioma is a type of aggressive thoracic cancer. Sadly, it is often diagnosed at
Several posters and presentations at the World Conference on Lung Cancer (WCLC) are dedicated to anew consensus definition of stage III NSCLC resectability. This initiative, led by the EORTC-Lung CancerGroup, involved the participation of many Belgian colleagues, including Dr. Mariana
In-depth stories
Prof dr Pasi Jänne, medical oncologist at the Dana Farber Cancer Institute, Boston, MA, USA presented the primary results of the DESTINY-Lung02 study evaluating 2 doses of trastuzumab deruxtecan (T-DXd) in patients with HER2-mutant metastatic non-small cell lung cancer (NSCLC).
Prof dr Pasi Jänne, medical oncologist at the Dana Farber Cancer Institute, Boston, MA, USA presented the outcomes of the FLAURA study during the presidential symposium at WCLC. FLAURA2 is a global, phase III, open-label, randomized study evaluating the efficacy
Prof dr Paul Van Schil, thoracic surgeon from Antwerp University Hospital and the new president of IASLC, took the time for an interview about the role of surgery for mesothelioma. He dives into the results of the EORTC 1205 study,
Prof Dr David Harpole, a thoracic surgeon at Duke University Medical Center in Durham, North Carolina, was one of the researchers involved in the AEGEAN study. The study examined the effectiveness of neoadjuvant durvalumab and chemotherapy, followed by adjuvant durvalumab
During an educational session at WCLC, Prof Dr Yolande Lievens, a radiation oncologist from Ghent University, gave a presentation on the topic of oligoprogression. She began by explaining that there is no clear agreement on the definition of oligoprogression and
During a recent update of the TRIDENT-1 trial, Prof Dr Byoung Chul Cho, a medical oncologist at Yonsei Cancer Center in Seoul, South Korea, presented positive results for repotrectinib, a next-generation ROS1 tyrosine kinase inhibitor (TKI) in patients with locally
Sarah Haesevoets is a PhD student at Hasselt University, and she works as a physiotherapist clinician-researcher at hospitals in Hasselt (Jessa Ziekenhuis) and Genk (Ziekenhuis Oost-Limburg). Her research focuses on physical activity for patients with lung cancer, and she recently
Poster selection
Prof dr Helmut Prosch, radiologist at the Medical University of Vienna, Austria presented the SOLACE project. SOLACE provides a modular framework (toolbox) for individualised approaches for lung cancer screening on a national or regional level to ensure the implementation and
Dr Eleni Xenophontos, a medical oncologist and clinical research physician at the European Organisation for Research and Treatment of Cancer (EORTC) in Brussels, presented a systematic literature review that was part of a global EORTC Lung Cancer Group initiative to
Prof Dr Yolande Lievens, a radiation oncologist from Ghent University, presented data from the Lung PLUS study, a monocentric prospective longitudinal study in patients with early-stage non-small cell lung cancer who received stereotactic body radiotherapy. At WCLC, data on patient-reported
Dr Marco Tagliamento, medical oncologist at Gustave Roussy Institute in Villejuif, France, presented outcomes of the CHIC study, aiming to explore clonal hematopoiesis in patients with advanced non-small cell lung cancer.
Dr Mariana Brandao, medical oncologist at Jules Bordet Institute in Brussels, presented the multidisciplinary clinical case review by a pan-European expert panel that was one of the three initiatives from the EORTC – Lung Cancer Group to establish a consensus
In a recent presentation, Prof Dr Julie Brahmer, a medical oncologist at the Johns Hopkins Kimmel Cancer Center in Baltimore, MD, USA, analyzed the CheckMate 227 study. The study examined the effectiveness of first-line treatment with nivolumab plus ipilimumab in
Prof Karim Vermaelen, medical oncologist from UZ Ghent presents the results of a first-in-human study with an mRNA-loaded dendritic cell vaccine in resected lung cancer patients.